drug_type
RELEVANT_DRUG
intervention_type
Viral vector therapeutic vaccine
drug_description
Replicating arenavirus-based therapeutic cancer vaccine (lymphocytic choriomeningitis virus vector) encoding non-oncogenic HPV16 antigens to elicit tumor-specific cytotoxic T-cell responses.
nci_thesaurus_concept_id
C167349
nci_thesaurus_preferred_term
HPV E6/E7-encoding Arenavirus Vaccine HB-201
nci_thesaurus_definition
A cancer vaccine consisting of a replication-attenuated arenavirus lymphocytic choriomeningitis virus (LCMV) encoding the inactivated fusion protein of the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) serotype 16, with potential immunomodulating and antineoplastic activities. Upon administration, HPV E6/E7-encoding arenavirus vaccine HB-201 induces expression of the E6/E7 proteins and stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.
drug_category
GENE THERAPY
drug_class
Vaccine
drug_delivery_route
Intravenous
drug_mechanism_of_action
Replicating arenavirus (LCMV) vector that delivers and expresses non-oncogenic HPV16 E6/E7 antigens in vivo to prime and expand HPV16-specific cytotoxic T lymphocytes, leading to immune-mediated lysis of HPV16-positive tumor cells.
drug_name
HB-201
nct_id_drug_ref
NCT06513884